Business Description
Bioxytran Inc
NAICS : 325412
SIC : 2834
ISIN : US9034102072
Description
Bioxytran Inc is a biopharmaceutical company. The company is engaged in developing anti-necrosis drugs that treat a variety of medical conditions resulting from Ischemia. It is also focusing on the development and commercialization of treatments to prevent catastrophic brain damage resulting from hypoxic conditions following brain stroke. Its product candidate, BXT-25, is an anti-necrosis drug that carries oxygen to tissues when the flow of blood is blocked.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.04 | |||||
| Equity-to-Asset | -6.82 | |||||
| Debt-to-Equity | -0.86 | |||||
| Debt-to-EBITDA | -0.35 | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -26 | |||||
| 3-Year FCF Growth Rate | 20.6 | |||||
| 3-Year Book Growth Rate | 16.3 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 39.39 | |||||
| 9-Day RSI | 42.71 | |||||
| 14-Day RSI | 44.8 | |||||
| 3-1 Month Momentum % | 22.46 | |||||
| 6-1 Month Momentum % | -17.13 | |||||
| 12-1 Month Momentum % | -5.81 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.03 | |||||
| Quick Ratio | 0.03 | |||||
| Cash Ratio | 0.03 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -14.3 | |||||
| Shareholder Yield % | 11.03 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROA % | -1895.41 | |||||
| ROIC % | -164.96 | |||||
| 3-Year ROIIC % | -177.59 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -3.21 | |||||
| EV-to-EBITDA | -3.22 | |||||
| EV-to-FCF | -42.02 | |||||
| Earnings Yield (Greenblatt) % | -31.15 | |||||
| FCF Yield % | -2.8 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:BIXT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Bioxytran Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.012 | ||
| Beta | 5.24 | ||
| 3-Year Sharpe Ratio | 0.62 | ||
| 3-Year Sortino Ratio | 8.67 | ||
| Volatility % | 63.5 | ||
| 14-Day RSI | 44.8 | ||
| 14-Day ATR ($) | 0.00539 | ||
| 20-Day SMA ($) | 0.09365 | ||
| 12-1 Month Momentum % | -5.81 | ||
| 52-Week Range ($) | 0.071 - 0.174 | ||
| Shares Outstanding (Mil) | 85.78 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Bioxytran Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Bioxytran Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Bioxytran Inc Frequently Asked Questions
What is Bioxytran Inc(BIXT)'s stock price today?
The current price of BIXT is $0.09. The 52 week high of BIXT is $0.17 and 52 week low is $0.07.
When is next earnings date of Bioxytran Inc(BIXT)?
The next earnings date of Bioxytran Inc(BIXT) is 2025-01-29 Est..
Does Bioxytran Inc(BIXT) pay dividends? If so, how much?
Bioxytran Inc(BIXT) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers